Welcome to THAC – The Healthy Aging Company
At THAC, we are dedicated to revolutionizing the treatment of diabetes and its neurologic and neurodegenerative complications and other age-related conditions through cutting-edge innovation.
Our Mission
Our mission is to develop game-changing therapies that address unmet medical needs and improve the lives of millions worldwide.
The Problem
Tackling the Global Epidemic of Diabetes and Age-Related Diseases
As society ages, age-related diseases are reaching epidemic proportions, posing immense challenges to healthcare systems and economies worldwide:
90%
of older adults have at least one chronic condition, nearly 80% have two or more
Global Health Crisis
Conditions such as cardiovascular disease, obesity, diabetes, and Alzheimer’s are now global health crises
80%
Age related diseases represent 80% of the US Medicare budget
$30 trillion
Age-related diseases are projected to cost over $30 trillion over the next 20 years
Diabetes and Diabetes-associated complications are major drivers of age-related diseases.
Despite major improvement of the treatment of Diabetes type II with GLP1 Receptor Agonists, diabetic neuropathy and diabetes-associated cognitive disorders and Alzheimer’s disease are still major unmet medical needs.
« At THAC, we are committed to addressing these challenges head-on with innovative therapies designed to improve lives and transform healthcare for a healthier, more sustainable future ».
Leveraging our expertise in biopharmaceutical research, we focus on:
Type 2 Diabetes Mellitus (T2DM) and associated complications
Diabetic Neuropathy
Cognitive disorders and Alzheimer’s Disease
Other conditions associated with aging
Our Solution: ALF-5755 – A Breakthrough Therapy
At THAC, we are leading the charge with ALF-5755, an innovative therapy designed to directly target the root causes of age-related diseases, offering hope for millions:
With ALF-5755, we are transforming the way age-related diseases are treated, improving patient outcomes, and redefining the future of healthcare.
THAC is a resident at The Institute of Diabetes,
Paris (France)
and at the University of South Florida (US)
Explore Our Blog
[PRESS RELEASE] Lancement du CSIS : Lyse Santoro, Personnalité Qualifiée du Conseil Stratégique des Industries de Santé (CSIS) 2021, THAC participe aux travaux du CSIS
[PRESS RELEASE] Lancement du Conseil stratégique des industries de[…]
Contact us
♦ Our location in France
Cochin Hospital – APHP
Incubateur Paris Biotech Santé
24 Boulevard du Faubourg Saint Jacques
75014 Paris, France
♦ Our location in the United States
University of South Florida
USF Connect Incubator
3702 Spectrum Blvd.
Tampa, FL 33612, USA